The Rabies drugs in development market research report provides comprehensive information on the therapeutics under development for Rabies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rabies. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rabies and features dormant and discontinued products.

GlobalData tracks 66 drugs in development for Rabies by 54 companies/universities/institutes. The top development phase for Rabies is preclinical with 26 drugs in that stage. The Rabies pipeline has 56 drugs in development by companies and ten by universities/ institutes. Some of the companies in the Rabies pipeline products market are: Changchun Bcht Biotechnology, AIM Vaccine and Chongqing Zhifei Biological Products.

The key targets in the Rabies pipeline products market include Rabies virus Glycoprotein (G).

The key mechanisms of action in the Rabies pipeline product include Rabies virus Glycoprotein (G) Inhibitor with seven drugs in Phase III. The Rabies pipeline products include six routes of administration with the top ROA being Intramuscular and ten key molecule types in the Rabies pipeline products market including Vaccine, and Monoclonal Antibody.

Rabies overview

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, difficulty swallowing, excitability, fever, and convulsions. The predisposing factors include exposure to wildlife and exposure to pets that are not vaccinated.

For a complete picture of Rabies’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.